Log in to search using one of your social media accounts:

 

Skin cancer warning: THIS mark on your nails could be a symptom of deadly condition
SKIN cancer symptoms usually include moles, lumps and ulcers that change in appearance, however a dark stripe - or stripes - running down a nail could be a sign of a particular form of melanoma. (Source: Daily Express - Health)
Source: Daily Express - Health - September 21, 2017 Category: Consumer Health News Source Type: news

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
FRANKFURT (Reuters) - European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. (Source: Reuters: Health)
Source: Reuters: Health - September 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Melanoma (Skin Cancer) Quiz: Symptoms & Signs
Title: Melanoma (Skin Cancer) Quiz: Symptoms& SignsCategory: MedicineNet QuizCreated: 6/19/2012 12:00:00 AMLast Editorial Review: 9/20/2017 12:30:16 PM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 20, 2017 Category: Cancer & Oncology Source Type: news

Slowly proliferating melanoma cells with high metastatic properties
(The Wistar Institute) A study conducted at The Wistar Institute has led to the identification of a slowly proliferating and highly invasive melanoma cell subpopulation, characterized by production of a protein associated with invasive behavior. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Penn researchers identify new target, develop new drug for cancer therapies
(University of Pennsylvania School of Medicine) Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to target that enzyme resistant to treatment. Researchers were able to use this finding to develop a drug that successfully inhibits tumor growth of melanoma as well as pancreatic and colorectal cancer in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Tumor-infiltrating B lymphocytes promote melanoma progression & resistance to therapy
(The Wistar Institute) In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ('TABs') in melanoma progression and resistance to targeted therapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 19, 2017 Category: Biology Source Type: news

Doctor Hazel, an AI aimed at skin cancer detection, is latest in a long line
Engineers participating in a hackathon last weekend demonstrated an artificial intelligence that they say could someday detect cancerous moles, TechCrunch reports. (Source: mobihealthnews)
Source: mobihealthnews - September 18, 2017 Category: Information Technology Source Type: news

' Follow the Money' in Extreme Skin Cancer Care'Follow the Money' in Extreme Skin Cancer Care
Specialists report a rise in every ultraviolet-related type of skin cancer, but controversy over excessive treatment persists.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2017 Category: Consumer Health News Tags: Dermatology News Source Type: news

Skin Cancer Prevention Strategies Needed in Work Settings
High occupational UV exposure tied to two - fold increase in skin cancer risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 16, 2017 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Nursing, Oncology, Journal, Source Type: news

Life- and Eye-Saving New Treatments for Uveal Melanoma Life- and Eye-Saving New Treatments for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 15, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Tailored Treatment for Head-and-Neck Cancer Mystery
Treatment TermsHead and Neck Cancer Overview Rob Vaughn found a lump on his neck that turned out to be cancer that had spread from somewhere else in his body. The trouble was, doctors couldn ’t find the original site of the cancer. That made his treatment decisions difficult -- until two Duke specialists offered him options, including the option for watchful waiting instead of extensive treatment. Hero Image20170914_robvaughn_neckcancer_083_herocrop.jpg Preview Image Content Blocks Header A Search for the Source of Cancer ContentVaughn, a Charlotte, NC, father of two, was 47 and in good health when he felt th...
Source: dukehealth.org: Duke Health News - September 15, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

FDG-PET/CT contributes to anal cancer follow-up
Given its high sensitivity and negative predictive value, French researchers...Read more on AuntMinnie.comRelated Reading: AI algorithm can classify bone lesions on PET/CT images FDG-PET/CT foretells melanoma therapy response New PET tracer could work well for prostate cancer SNMMI: PET/CT with prostate agent changes therapy plans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 15, 2017 Category: Radiology Source Type: news

Does the Mole Always Come Before the Melanoma? Does the Mole Always Come Before the Melanoma?
Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Breakthrough Treatments Arriving for Uveal Melanoma Breakthrough Treatments Arriving for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Eye-Saving New Treatment Options for Uveal Melanoma Eye-Saving New Treatment Options for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 14, 2017 Category: Pathology Tags: Ophthalmology News Source Type: news

Consuming a diet rich in tomatoes may help prevent skin cancer
(Natural News) A compelling new study implies the use of food as medicine. Researchers from the Ohio State University said that daily tomato consumption can reduce the risk of developing skin cancer by half, but only if you’re a male. Females, it was noted, showed no statistically significant difference between tomato intake and skin cancer... (Source: NaturalNews.com)
Source: NaturalNews.com - September 14, 2017 Category: Consumer Health News Source Type: news

Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data
Three-year survival rates with advanced melanoma are 52% with nivolumab and 34% with ipilimumab, but 58% with a sequential combination of the two, according to the latest results comparing the two anticancer biologics separately and together.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Researchers find hint of a link between flu vaccine and miscarriage
Researchers studying the impact of the flu vaccine in pregnancy have found a possible link between miscarriage early in pregnancy in women who received the flu vaccine two years in a row. It’s the first study to identify a potential link between miscarriage and the flu vaccine and the first to assess the effect of repeat influenza […]Related:Melinda Gates decries ‘loss of U.S. leadership’ in global aidFormer CDC chief launches $225 million global health initiativeNew clinical trial might change the standard treatment for melanoma (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - September 13, 2017 Category: Consumer Health News Source Type: news

What to know about a study of flu vaccine and miscarriage
Researchers studying the flu vaccine in pregnancy have found a hint of a possible link between miscarriage early in pregnancy and the flu vaccine in women who received a certain version of the vaccine two years in a row. It’s the first study to identify a potential link between miscarriage and the flu vaccine and the first […]Related:Melinda Gates decries ‘loss of U.S. leadership’ in global aidFormer CDC chief launches $225 million global health initiativeNew clinical trial might change the standard treatment for melanoma (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - September 13, 2017 Category: Consumer Health News Source Type: news

FDG-PET/CT contributes to anal cancer follow-up assessment
Given its high sensitivity and negative predictive value, French researchers...Read more on AuntMinnie.comRelated Reading: AI algorithm can classify bone lesions on PET/CT images FDG-PET/CT foretells melanoma therapy response New PET tracer could work well for prostate cancer SNMMI: PET/CT with prostate agent changes therapy plans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 13, 2017 Category: Radiology Source Type: news

Wondering if that mole is cancerous? Look at illustrations, not photos
(Brigham Young University) Melanoma kills more than 50,000 people worldwide annually. But because early detection dramatically improves prognoses, a BYU professor is working to help people better identify problematic moles. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 13, 2017 Category: Cancer & Oncology Source Type: news

Dabrafenib, Trametinib Beneficial in Resected Melanoma
Rate of relapse - free survival up for resected stage III melanoma with BRAF V600E, V600K mutations (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2017 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

UCLA starts Phase I stem cell trial for cancers with NY-ESO-1 tumour marker
The University of California, Los Angeles (UCLA) has started a Phase I clinical trial to evaluate new genetically engineered blood-forming stem cells to treat cancers such as melanoma and sarcoma with a specific tumour marker called NY-ESO-1. (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Two Adjuvant Wins for Resected Melanoma (CME/CE)
(MedPage Today) -- Nivolumab, targeted combination slow recurrence in high-risk disease (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 12, 2017 Category: General Medicine Source Type: news

Adjuvant Nivolumab Tops Ipilimumab in Melanoma
Longer recurrence - free survival for stage IIIB, IIIC, IV melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 12, 2017 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

Cochrane Skin Group celebrate 20 years of improving treatment of skin diseases
World-leading dermatologists and their patients are celebrating huge improvements in the treatment of skin diseases like skin cancer, psoriasis, and acne as theCochrane Skin Group marks its 20th anniversary this week.   The effects of the 120 plus published Cochrane Skin Reviews have been far-reaching and have had real impacts on patient care. These include skin cancer, skin allergies, and acne, blistering diseases, hair disorders like alopecia, fungal infections and psoriasis as well as tropical parasitic disea ses.The group is coordinated by the University of Nottingham ’s Centre of Evidence Based Dermatology ...
Source: Cochrane News and Events - September 12, 2017 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Medical News Today: Advanced melanoma: Groundbreaking trials could transform treatment
An immunotherapy and targeted therapy both promise to bring closer the day when melanoma is a disease that people live with instead of die from. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 12, 2017 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

Zimbabwe: Health Minister Visits Cancer Plagued Children
[263Chat] Government is set to assist the two Epworth girls affected by Zeroderma Pigmentosa and Skin Cancer with medical attention, Health and Child Care minister, Dr David Parirenyatwa has said. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 12, 2017 Category: African Health Source Type: news

New Adjuvant Option for BRAF Melanoma New Adjuvant Option for BRAF Melanoma
Combined targeting with BRAF and MEK inhibitors will soon move into the adjuvant setting for treating BRAF-V300-positive stage III melanoma, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Clear Benefit With Adjuvant Nivolumab in Resected Melanoma Clear Benefit With Adjuvant Nivolumab in Resected Melanoma
Adjuvant nivolumab significant improves relapse-free survival and reduces toxicity in comparison with ipilimumab in stage III/IV resected melanoma for patients at risk for relapse, trial results reveal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Zimbabwe: Govt Comes to Minors' Aid
[The Herald] Government yesterday intervened and ensured two minors with a rare skin cancer condition were admitted at Parirenyatwa Hospital in Harare and are attended to by specialists. The children, Bridget Mandimutsira of Mabvuku and Natasha Matimba of Norton, were no longer receiving medical attention after doctors at the hospital had failed to provide a solution to their condition. This saw Health and Child Care Minister David Parirenyatwa intervening. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 12, 2017 Category: African Health Source Type: news

Researchers report positive results from two melanoma trials in Australia
Researchers at Melanoma Institute Australia have reported positive results from two clinical trials, COMBI-AD and CheckMate 238, conducted to stop and prevent melanoma progression. (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news

Immune-focused drug may be new weapon against advanced melanoma
New research suggests that Opdivo is more effective than the current standard of care for patients who've had surgery to remove advanced tumors. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 11, 2017 Category: Consumer Health News Source Type: news

Melanoma can be prevented by eating fast food
Boston University researchers studied mice to see if a palmitic acid, a fat found in fast food, could prevent melanoma. Red heads, fair skinned and those who tan are most at risk for this skin cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - September 11, 2017 Category: Consumer Health News Source Type: news

Immune-focused drug targets advanced melanoma
The drug is a more effective option for patients who've had surgery to remove advanced tumors, according to new research (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 11, 2017 Category: Consumer Health News Source Type: news

Immune-Focused Drug New Weapon Against Melanoma
In head-to-head trial, Opdivo outperformed a similar drug, and with fewer side effects (Source: WebMD Health)
Source: WebMD Health - September 11, 2017 Category: Consumer Health News Source Type: news

Immune - Focused Drug May Be New Weapon Against Advanced Melanoma
In head - to - head trial, Opdivo outperformed a similar drug, and with fewer side effects (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 11, 2017 Category: Cancer & Oncology Tags: Family Medicine, Nursing, Oncology, Pharmacy, News, Source Type: news

Immune-Focused Drug May Be New Weapon Against Advanced Melanoma
In head-to-head trial, Opdivo outperformed a similar drug, and with fewer side effects Source: HealthDay Related MedlinePlus Pages: Medicines, Melanoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 11, 2017 Category: Consumer Health News Source Type: news

Immune-Focused Drug, Opdivo, May Be New Weapon Against Advanced Melanoma
MONDAY, Sept. 11, 2017 -- New research suggests that Opdivo -- a drug that works with the immune system to fight melanoma -- is more effective than the current standard of care for patients who've had surgery to remove advanced tumors. The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 11, 2017 Category: General Medicine Source Type: news

Immune-Focused Drug May Be New Weapon Against Advanced Melanoma
MONDAY, Sept. 11, 2017 -- New research suggests that Opdivo -- a drug that works with the immune system to fight melanoma -- is more effective than the current standard of care for patients who've had surgery to remove advanced tumors. The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 11, 2017 Category: General Medicine Source Type: news

Immune-Focused Drug May Be New Weapon Against Advanced Melanoma
Title: Immune-Focused Drug May Be New Weapon Against Advanced MelanomaCategory: Health NewsCreated: 9/11/2017 12:00:00 AMLast Editorial Review: 9/11/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 11, 2017 Category: Cancer & Oncology Source Type: news

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf ® (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma. (Source: Roche Media News)
Source: Roche Media News - September 11, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf ® (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma. (Source: Roche Investor Update)
Source: Roche Investor Update - September 11, 2017 Category: Pharmaceuticals Source Type: news

Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
(European Society for Medical Oncology) Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine. The anti-programmed death-1 (PD-1) antibody nivolumab led to better relapse-free survival, with fewer side effects than ipilimumab. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma
(European Society for Medical Oncology) Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

Stage III skin cancer could be cured by Australians
Investigators at Melanoma Institute Australia have prevented the spread of disease in Stage III melanoma patients whose tumours have been surgically removed. (Source: the Mail online | Health)
Source: the Mail online | Health - September 11, 2017 Category: Consumer Health News Source Type: news

Immune-Focused Drug May Be New Weapon Against Advanced Melanoma
In head-to-head trial, Opdivo outperformed a similar drug, and with fewer side effects (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

Regeneron and Sanofi receive FDA ’s breakthrough therapy status for CSCC treatment with cemiplimab
US-based Regeneron Pharmaceuticals and French company Sanofi have received breakthrough therapy designation status for cemiplimab (REGN2810) from the US Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 10, 2017 Category: Pharmaceuticals Source Type: news

Novartis posts a win, Roche a flop in skin cancer trials
ZURICH/MADRID (Reuters) - Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. (Source: Reuters: Health)
Source: Reuters: Health - September 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news